Dan--here is the article--this should be the very first in a string of good news for CYTO over the next several months--the financing announcement is the on the Street is waiting for. I hear it will be good. Unfortunately the results of the P1 are not detailed in the release. I hope there will be future releases soon. The P2s should soon be finished if they are not already.
>>Monday September 22 11:44 AM EDT Company Press Release
CYTOGEN Participates In Prostate Cancer Awareness Week
PRINCETON, N.J., Sept. 22 /PRNewswire/ -- CYTOGEN Corporation (Nasdaq:CYTO) announced a variety of media events ranging from product information on CNBC television to published clinical trial results, all of which are a part of the Company's active participation in Prostate Disease Awareness Month (September) and Prostate Cancer Awareness Week (September 21-27, 1997).
CYTOGEN believes the upcoming events will provide valuable information to physicians, patients and their families on current developments in the care for this disease and welcomes the opportunity for its products to be featured.
``CYTOGEN is pleased to participate in Prostate Cancer Awareness Week. Developing products to better diagnose and treat prostate cancer has been a major area of commitment for CYTOGEN. With the approval and launch this year of ProstaScint(R) (kit for the preparation of indium In 111 Capromab Pendetide) and Quadramet(R) (Samarium Sm 153 Lexidronam Injection), along with the encouraging clinical findings with the PSMA vaccine, there is much positive news from CYTOGEN to bring to physicians, prostate cancer patients and their families. Broader awareness of these important developments will ensure that people know about these new options for treatment and can help to relieve the suffering from this dreaded disease,'' commented Thomas J. McKearn, CYTOGEN's Chief Executive Officer, President and Chairman.
The Company's Quadramet product, a drug developed as a treatment for patients with severe chronic pain associated with cancer that spreads to the bone, will be the subject of a segment included in CNBC's Today's Health program scheduled to air on Sunday, September 28 at 3:00 p.m. (EST). The segment will feature a physician who has used Quadramet as well as a cancer patient who has received the product. The Fall issue of Family Urology will contain a pain management article by Dr. Oliver Sartor, Associate Professor of Oncology, Louisiana State University, which discusses various cancer pain management options including Samarium Sm 153 Lexidronam Injection.
The Company's ProstaScint prostate cancer imaging agent, a non-invasive (non-surgical) diagnostic agent available to prostate cancer patients considered at high risk for cancer spread outside the prostate, is to be described in Family Circle's Fall special issue entitled Your Family's Health in a prostate cancer patient's story.
The recently published September issue of ``The Prostate'' contains an article detailing results from a phase I clinical trial conducted using CYTOGEN's PSMA (prostate specific membrane antigen) technology in the development of a prostate cancer vaccine. The clinical trials are being conducted by the Pacific Northwest Cancer Foundation located in Seattle, Washington.
The Company is also participating in a series of Prostate Cancer Patient Advocacy Meetings, which will address the roles of ProstaScint and Quadramet in meeting the needs of prostate cancer patients. These meetings are scheduled for September 27th in Philadelphia, PA and Morristown, NJ; October 3rd in Orlando, FL; October 16th in New York City; October 31st and November 1st in Columbia, SC; November 12th at the New Jersey Prostate Cancer Summit, New Brunswick, NJ; and December 11th at the Mercer County Prostate Cancer Support Group in New Jersey.
For the most current news on CYTOGEN and a current listing of PIE(TM) (Partners In Excellence) sites, visit the Company's web site at www.cytogen.com, or call 800-758-5804, extension 224650, to receive news releases by facsimile.
CYTOGEN is a biopharmaceutical company engaged in the development, manufacture and commercialization of products for the targeted delivery of diagnostic and therapeutic substances directly to disease sites. CYTOGEN has demonstrated its ability to develop new technology from early discovery through clinical development, regulatory approval and commercial-scale biologic manufacturing.
Information in this press release which is not historical is forward- looking and involves risks and uncertainties. Actual results may differ materially, for reasons discussed in the Company's filings including those related to the Company's and the Company's partners' ability to successfully markets its products. << |
